Lantheus mulls potential $7B sale after Curium takeover offer

Lantheus Holdings (LNTH) is said to be considering a potential $7 billion sale after receiving a takeover offer from Curium Pharma, a private‑equity backed nuclear‑medicine company, according to a Bloomberg News report published on May 22, 2026.

Lantheus has a market capitalization of about $6.15 billion, so the reported $7 billion valuation in the Curium offer would represent a premium of roughly 13–14% to its current equity value.

The two companies have been in talks about a potential deal that could be finalized in the coming weeks, but no final decision has been made and there is no guarantee that negotiations will lead to a transaction.

Lantheus declined to comment on the Bloomberg report, and Curium has not immediately responded to requests for comment.

Lantheus is a U.S.‑based radiopharmaceutical company known for its diagnostic imaging products, while Curium develops and manufactures nuclear‑medicine products and is backed by private‑equity firm CapVest Partners; Curium itself was valued at about $7 billion last year in a continuation‑fund financing round.

Lantheus shares were trading nearly 2% lower in extended trading after the report, suggesting investors are cautious about the premium implied in the deal and the potential regulatory and integration risks.